Name | 6α-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid |
---|---|
Synonyms |
Faropenemsodiumhemipentahydrate
6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid (5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furanyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (+)-(5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furyl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (5R,6S)-6-[1(R)-hydroxyethyl]-2-[2(R)-tetrahydrofuryl]penem-3-carboxylic acid (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-keto-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (5R,6S)-6-[(1R)-1-Hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid (+)-(5R,6S)-6-((1R)-1-Hydroxyethyl)-7-oxo-3-((2R)-tetrahydro-2-furyl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid 6α-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid Faropenem sodium hemipentahydrate (5R,6S,8R,2'R)-2-(2'-tetrahydrofuryl)-6-(1-hydroxyethyl)-2-penem-3-carboxylic acid FAROPENEM 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furanyl]-, (5R,6S)- 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid,6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furanyl]-,(5R,6S) FROPENEM faropenem free acid |
Description | Faropenem is a potent and orally active beta-lactam antibiotic. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many gram-positive and -negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Faropenem is developed as an oral prodrug, faropenem medoxomil, for the research of respiratory tract infections[1][2]. |
---|---|
Related Catalog | |
In Vitro | Faropenem is not active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, Pseudomonas aeruginosa or Stenotrophomonas maltophilia[1]. Faropenem is against all isolates of B. anthracis. The MIC values ranged from ≤0.06 to >64 μg/liter, and the MIC90 value is 0.5 μg/ml. The MIC90 value for Faropenem is lower than that observed for other β-lactams, such as Meropenem, Amoxicillin-clavulanate, and Penicillin, for which the MIC90 values are 4 μg/ml, 4 μg/ml, and 8 μg/ml, respectively[2]. |
In Vivo | Faropenem ( i.p. at 24 h postchallenge at 4-, 6-, and 12-h intervals; 10, 20, 40, and 80 mg/kg/day; 14 days) demonstrates a high level of activity against B. anthracis in the murine post-exposure prophylaxis inhalation model[1]. |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 570.2±50.0 °C at 760 mmHg |
Molecular Formula | C12H15NO5S |
Molecular Weight | 285.316 |
Flash Point | 298.7±30.1 °C |
Exact Mass | 285.067108 |
PSA | 112.37000 |
LogP | -0.45 |
Vapour Pressure | 0.0±3.6 mmHg at 25°C |
Index of Refraction | 1.668 |
Storage condition | 2-8°C |
Risk Phrases | R20/21/22 |
---|
~% 106560-14-9 |
Literature: WO2008/12830 A1, ; Page/Page column 7-8 ; |
Precursor 1 | |
---|---|
DownStream 0 |